NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
Clinical Trials
12 trialsNCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT03703063 2021-01-27
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Phase 1 Unknown
NCT03825328 2019-01-31
A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )
Harbin Medical University
Phase 2 Unknown
NCT03636308 2018-08-17
ASAGPAC
Peking University
Phase 2 Unknown
NCT02975141 2018-08-13
AFFECT
Ludwig-Maximilians - University of Munich
Phase 1 Unknown
NCT03435289 2018-02-19
A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer
Atlantic Health System
Phase 1 Unknown
NCT01971281 2017-09-13
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
NovoCure Ltd.
Phase 1/2 Unknown
NCT01964534 2017-01-31
AFUGEM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT02506842 2016-08-11
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
Fudan University
Phase 3 Unknown
NCT01934634 2015-11-10
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
US Oncology Research
Phase 1 Unknown